Oliver Strub - Santhera Pharmaceuticals Gen VP
| SANN Stock | CHF 10.40 0.47 3.39% |
Insider
Oliver Strub is Gen VP of Santhera Pharmaceuticals Holding
| Age | 60 |
| Phone | 41 61 906 89 50 |
| Web | https://www.santhera.com |
Santhera Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4918) % which means that it has lost $0.4918 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (13.1615) %, meaning that it generated substantial loss on money invested by shareholders. Santhera Pharmaceuticals' management efficiency ratios could be used to measure how well Santhera Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Santhera Pharmaceuticals Holding has accumulated 27 M in total debt with debt to equity ratio (D/E) of 196.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Santhera Pharmaceuticals has a current ratio of 2.15, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Santhera Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Santhera Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Santhera Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Santhera to invest in growth at high rates of return. When we think about Santhera Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for orphan and other diseases with high unmet medical needs in the European countries. Santhera Pharmaceuticals Holding AG is headquartered in Pratteln, Switzerland. SANTHERA N operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 114 people. Santhera Pharmaceuticals Holding (SANN) is traded on SIX Swiss Exchange in Switzerland and employs 39 people. Management Performance
| Return On Equity | -13.16 | |||
| Return On Asset | -0.49 |
Santhera Pharmaceuticals Leadership Team
Elected by the shareholders, the Santhera Pharmaceuticals' board of directors comprises two types of representatives: Santhera Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Santhera. The board's role is to monitor Santhera Pharmaceuticals' management team and ensure that shareholders' interests are well served. Santhera Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Santhera Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eva Kalias, Head Communications | ||
| FCMA CGMA, Chief Officer | ||
| Shabir MD, Chief Officer | ||
| Thomas Meier, Founder Chairman | ||
| Dario Eklund, Chief Officer | ||
| Neville MD, Head Management | ||
| Gnther Metz, Head VP | ||
| Sarah HolmesKlotz, Head Culture | ||
| Oliver Strub, Gen VP | ||
| Marc Schrader, Head Operations |
Santhera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Santhera Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -13.16 | |||
| Return On Asset | -0.49 | |||
| Operating Margin | (386.18) % | |||
| Current Valuation | 58.16 M | |||
| Shares Outstanding | 61.81 M | |||
| Shares Owned By Insiders | 18.77 % | |||
| Shares Owned By Institutions | 3.50 % | |||
| Price To Earning | (7.01) X | |||
| Price To Book | 30.52 X | |||
| Price To Sales | 276.19 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Santhera Stock Analysis
When running Santhera Pharmaceuticals' price analysis, check to measure Santhera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santhera Pharmaceuticals is operating at the current time. Most of Santhera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Santhera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santhera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Santhera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.